The stars have aligned for the third time between invoX Pharma’s F-star and Takeda as the duo gets to work on another antibody pact, with an aim to create new immunotherapies for undisclosed cancers.
invoX Pharma Completes Acquisition of F-star Therapeutics, Inc.
F-star Therapeutics Announces CFIUS Clearance for Proposed Acquisition by invoX Pharma
After taking several months to review F-star’s proposed sale to a Chinese company, the US government’s Committee on Foreign Investment in the United States (CFIUS) has finally given its blessing for the deal.
F-star Therapeutics Stock Jumps on Extension to Invox Pharma Merger Deadline
With the clock ticking on F-star Therapeutics’ takeover by a Chinese buyer, the companies are still scrambling to remove a hold on the deal from the US government’s Committee on Foreign Investment in the United States.
invoX Pharma and F-star Therapeutics issue Joint Statement
F-star Therapeutics won’t yet be able to close its deal with its Chinese buyer, after the US government’s Committee on Foreign Investment in the United States panel put a hold on the takeover, citing national security risks.
Why: F-star Therapeutics provides an update regarding its Agreement and Plan of Merger, dated as of June 22, 2022, as amended by and among, the company, invoX Pharma Limited, Fennec Acquisition Incorporated, a wholly owned subsidiary of invoX, and Sino Biopharmaceutical Limited.
F-STAR THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits (form 8-K)